ArticlePediatric rheumatology online journal2025
The clinical features and outcome of Kawasaki disease combined with G6PD deficiency.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe characteristics and prognosis of Kawasaki disease (KD) patients with glucose-6-phosphate dehydrogenase deficiency (G6PDd) remain unknown. This study primarily aims to investigate whether G6PDd is an independent risk factor for persistent coronary artery lesions (CAL) in KD and secondarily to evaluate the prognosis of these patients without aspirin therapy.
methodsWe conducted a retrospective case-control study. All KD patients with G6PDd were included. The control group, consisting of KD patients with normal G6PD activity, was matched by age, sex and hospitalization period at a 1:3 ratio. The clinical features, proportion of high-risk KD, and incidence of CAL between the two groups were compared.
resultsThis study included 54 and 162 patients in the G6PDd and the control group, respectively. No differences were observed between the two groups in most clinical symptoms and laboratory indicators(all p > 0.05). The univariate analysis showed that G6PD deficiency was significantly associated with high-risk SANO classification (OR 3.51, 95% CI 1.60–7.72, p = 0.002). However, both groups had a similar proportion of non-SANO high-risk KD(16.67%, OR, 1.42; 95% CI, 0.60–3.35; p = 0.420). There were no significant differences in the incidence of persistent CAL beyond 8 weeks between the G6PDd group (without aspirin) and the control group (with aspirin) (12.77% vs. 6.21%; OR, 2.21; 95% CI, 0.76–6.44). Similarly, the prevalence of IVIG-resistant KD were comparable between two groups (8.51% vs. 8.70%; OR, 0.98; 95% CI, 0.31–3.12).
conclusionG6PD deficiency may not likely be a significantly risk factor for CAL in KD. SANO criteria may not be suitable for KD patients with G6PDd. Although aspirin is not routinely applied to KD patients with G6PDd, it seems unlikely have a major effect on the short-term prognosis of this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.